Advertisement
Advertisement
U.S. Markets open in 7 hrs 49 mins
Advertisement
Advertisement
Advertisement
Advertisement

Astellas Pharma Inc. (ALPMY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
15.30+0.09 (+0.59%)
At close: 03:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.21
Open15.33
Bid0.00 x 0
Ask0.00 x 0
Day's Range15.18 - 15.35
52 Week Range14.21 - 18.18
Volume78,086
Avg. Volume95,561
Market Cap28.7B
Beta (5Y Monthly)0.58
PE Ratio (TTM)27.37
EPS (TTM)0.56
Earnings DateN/A
Forward Dividend & Yield0.41 (2.66%)
Ex-Dividend DateMar 29, 2022
1y Target Est17.97
  • PR Newswire

    Astellas Announces Management Structure

    Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the following changes to its management structure effective October 1, 2022.

  • Investor's Business Daily

    Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?

    Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday.

  • Benzinga

    Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say

    Earlier today, Seagen Inc (NASDAQ: FBI) and Astellas Pharma Inc (OTC: ALPMF) announced topline results from the phase 1b/2 EV-103 trial (KEYNOTE-869) cohort K of Padcev (enfortumab vedotin-ejfv) in metastatic urothelial carcinoma (mUC). Needham says that the results from Cohort K primarily live up to expectations. The management has previously indicated that results from Cohort K could be used to support accelerated approval in the 1L cis-ineligible mUC setting. See the Seagen Analyst Page here.

Advertisement
Advertisement